- Home
- Equities - Stocks - Shares
- Company Press Releases
- Nykode Therapeutics To Present At The 41st Annual J.P. Morgan Healthcare Conference
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
23 Dec 2022 11:00 CET
Issuer
NYKODE THERAPEUTICS ASA
Oslo, Norway, December 23, 2022 – Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that its Chief Executive
Officer Michael Engsig will present at the 41st Annual J.P. Morgan Healthcare
Conference on Monday, January 9, 2023 at 1:30 p.m. PT / 10:30 p.m. CET.
The live and archived webcast of the presentation can be accessed in the
Investors section of the Company’s website here:
https://nykode.com/investors/financial-reports-and-presentations/.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode’s modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which are essential for inducing
rapid, strong and long-lasting antigen specific immune responses and eliciting
efficacious clinical responses.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase 2 trial
for the treatment of cervical cancer; and VB10.NEO, an individualized cancer
neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of
the Roche Group. Additionally, Nykode is conducting a Phase 1/2 trial with
next-generation COVID-19 vaccine candidates.
The Company’s partnerships include Genentech within oncology, a multi-target
collaboration with Regeneron within oncology and infectious diseases and a
collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine
development.
Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics may be found at
http://www.nykode.com
Contact for Nykode Therapeutics ASA:
Chief Business Officer, Agnete Fredriksen
Nykode Therapeutics ASA
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
More information:
Access the news on Oslo Bors NewsWeb site
Source
Nykode Therapeutics ASA
Provider
Oslo Børs Newspoint
Company Name
NYKODE THERAPEUTICS ASA
ISIN
NO0010714785
Symbol
NYKD
Market
Oslo Børs